CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kazia Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kazia Therapeutics Ltd
Three International Towers Level 24
, 300 Barangaroo Avenue
Phone: +61 294724100p:+61 294724100 Sydney, NSW  2000  Australia Fax: +61 294760388f:+61 294760388
This company is no longer actively traded on any major stock exchange.
Business Summary
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20236/30/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director John E.Friend 52 8/11/2023 11/15/2021
Chief Financial Officer KarenKrumeich 1/1/2022 1/1/2022
Clinical & Regulatory Affairs Manager Lilischkis R.Kimberley
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Glioblast Pty Limited
Glioblast Pty Ltd
Kazia Laboratories Pty Limited
5 additional Business Names available in full report.

General Information
Number of Employees: 12 (As of 6/30/2014)
Outstanding Shares: 332,850,784 (As of 6/30/2024)
Shareholders: 3,204
Stock Exchange: ASX
Fax Number: +61 294760388
Email Address: info@kaziatherapeutics.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, January 30, 2025